Detalles de la búsqueda
1.
Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.
Mol Cancer Ther;
20(9): 1627-1639, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34389694
2.
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK.
Mol Cancer Ther;
20(10): 1757-1768, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34330842
3.
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2.
J Med Chem;
64(16): 12286-12303, 2021 08 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34387469
4.
Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2.
Mol Cancer Ther;
19(2): 525-539, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31748345
5.
Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.
J Clin Invest;
130(1): 258-271, 2020 01 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31581151
6.
ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
Mol Cancer Ther;
17(7): 1381-1391, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29695633
7.
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660).
J Med Chem;
61(16): 7314-7329, 2018 08 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30091600
8.
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2.
J Med Chem;
61(11): 4978-4992, 2018 06 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29775310
9.
DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.
Clin Cancer Res;
21(4): 925-33, 2015 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25480831
10.
Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.
ACS Med Chem Lett;
6(7): 798-803, 2015 Jul 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26191369
11.
Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models.
Mol Cancer Ther;
13(12): 2793-2804, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25349308
12.
Intra-ER sorting of the peroxisomal membrane protein Pex3 relies on its luminal domain.
Biol Open;
2(8): 829-37, 2013 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23951409
13.
Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination.
Cancer Chemother Pharmacol;
69(1): 155-64, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21630086
14.
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K.
Mol Cancer Ther;
11(8): 1789-98, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22576130
15.
A dual function for Pex3p in peroxisome formation and inheritance.
J Cell Biol;
187(4): 463-71, 2009 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-19948495
Resultados
1 -
15
de 15
1
Próxima >
>>